Clene Inc. (NASDAQ:CLNN) has made significant corporate moves, including amending its senior secured convertible promissory notes to extend the maturity date to August 2027. Monthly payments of $150,000 have been deferred, with the total debt amounting to $22.05 million against a market capitalization of $85.23 million. The company is currently facing financial challenges, reporting a negative EBITDA of $19.62 million over the past year. During its annual meeting, shareholders approved an increase of 1 million shares in the 2020 Stock Plan and elected new Class III directors, including Robert Etherington and Shalom Jacobovitz, for terms ending in 2029. Additionally, Deloitte & Touche LLP was confirmed as the independent accounting firm for fiscal year 2026. Clene is also pursuing an underwritten registered direct offering of 1 million shares at $7.00 per share, aiming for gross proceeds of around $7 million. Furthermore, the company plans to file for accelerated approval of its CNM-Au8 drug for amyotrophic lateral sclerosis (ALS) following a positive meeting with the U.S. Food and Drug Administration (FDA), which indicated that Clene's data could support a New Drug Application under the accelerated approval pathway.